Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Spark"s Play Pen -- Ignore unavailable to you. Want to Upgrade?

To: Spark who wrote (128)	3/20/2002 12:20:31 PM
From: Spark	Read Replies (1) \| Respond to of 6175

LCSG...this one claims it can cure cancer, Aids and Arthritis!! ROTFLOL!!... Monday March 18, 1:46 pm Eastern Time Press Release SOURCE: Shinn Capital Group, Inc. Shinn Capital Group Grants Two Licenses HONOLULU--(BUSINESS WIRE)--March 18, 2002--Shinn Capital Group, Inc. (SCG), a Hawaii based corporation, recently granted two licenses to work with its immunostimulant Tubercin. SCG has the exclusive worldwide rights for this compound developed and administered in South Korea for the last 14 years. It is the intent of SCG and the licensees to bring Tubercin, an immunostimulant that combats diseases such as Cancer, Aids and Arthritis, to the world markets through a variety of delivery methods. Tubercin was invented by Dr. Tai-Ho Chung of Kyungpook National University Medical School, Taegu, Korea. Tubercin is patented in the US, Japan and Korea (US Patent 6,274,356). T-19 Incorporated (OTCBB:LCSG - news) was granted a license to develop products for the worldwide retail and holistic marketplaces as well as the implementation of off shore clinics; and is currently working on a Nasal Spray that appears promising and should be available in the immediate future. Hard-To-Treat Diseases Inc. (HTTD), a wholly owned subsidiary of Gatlin Holdings, Inc. (OTCBB:GTNH - news) was granted a license to develop products for the Federal Drug Administration regulated marketplace as well as seek FDA approval. Shinn Capital Group, Inc. is very supportive of both HTTD and T-19 in their missions to make Tubercin available as quickly as possible to those who seek help. SCG is a privately held investment group with close ties to the South Korean medical community. Forward Looking Statements Statements contained in this press release, which are not historical facts, are forward-looking statements within the Meaning of The Private securities litigation reform Act of 1995 (the Act). Such forward-looking statements are necessary estimates reflecting the best judgment of the party making such statements based upon current information and involve a number of risks and uncertainties, which may affect the Company's business and prospects and cause actual results to differ materially from these statements. Forward-looking statements contained in this press release or in other public statements of the parties should be considered in light of those factors. There can be no assurances that such factors or other factors will affect the accuracy of such forward-looking statements. -------------------------------------------------------------------------------- Contact: SCG, Honolulu Ronald Shinn, 808/523-5800 or toll-free 866/523-5800